衰老和认知性:分子机制作为新的潜在治疗点
Ana Cordeiro1, Catarina Gomes2, Joana Bicker2
1Laboratory of Pharmacology, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal.
Drug discovery today
|July 11, 2024
概括
随着人们的年龄增长,理解认知性是开发新疗法与年龄相关的认知衰退的关键. 本综述探讨了分子因素和治疗策略,以增强大脑健康和延长健康寿命.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 分子生物学分子生物学
背景情况:
- 全球人口老龄化需要战略来延长寿命和健康寿命.
- 认知性对于在衰老期间保持生活质量至关重要.
- 了解与年龄相关的认知衰退及其分子基础至关重要.
研究的目的:
- 批判性地审查认知性的分子机制.
- 分析与年龄有关的认知衰退的新兴治疗策略.
- 综合动物和人类研究的见解.
主要方法:
- 文献审查和批判性评价.
- 对认知性的分子决定因素的分析.
- 对遗传和表观遗传因素的检查.
主要成果:
- 确定了影响认知性的关键分子途径.
- 评估治疗策略,包括药物重新定位,宏分子和细胞疗法.
- 综合了来自各种动物和人类研究的发现.
结论:
- 通过理解认知性,可以开发新的治疗途径.
- 准分子机制有可能缓解与年龄相关的认知衰退.
- 药物和细胞疗法的组合可能是有益的.
更多相关视频
10:13Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach
Published on: February 14, 2014
13.7K
08:17A Mouse Model of Orthopedic Surgery to Study Postoperative Cognitive Dysfunction and Tissue Regeneration
Published on: February 27, 2018
16.4K
相关概念视频
Aging
41
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
41
Cognitive Development During Adulthood
83
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
83
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
118
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
118
Mitochondria
12.0K
Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
12.0K
Alzheimer's Disease: Treatment
177
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
177
Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
